Sublingual B12: What the Absorption Route Really Changes

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

Sublingual B12 does change the absorption route, but the real bottleneck is intrinsic-factor biology, not whether the label says tablet or under-the-tongue. Normal vitamin B12 uptake saturates at about 1 to 2 mcg per meal, while only about 1.3% of a 1,000 mcg oral dose is absorbed passively after that. Small comparative studies have not shown a clear efficacy advantage for sublingual over oral replacement, but both can work when they deliver free crystalline B12 at a high enough dose. The MIHIYO Labs oral dissolving strip format matters here because unit-dose precision and fast oral contact are more useful than chasing headline milligrams.

Does sublingual B12 absorb better than oral B12?

Sometimes the route matters a lot. Sometimes it matters less than the dose and the chemistry of the B12 being delivered. That is the honest answer.

If a person is relying on normal food-bound B12 absorption, the route is fragile because the vitamin has to be released from food proteins in the stomach, bind intrinsic factor, and then be taken up in the distal ileum by a receptor-mediated system that saturates quickly.¹² With a high-dose oral or sublingual supplement that provides free crystalline B12, a small fraction can still cross by passive diffusion even when intrinsic-factor absorption is impaired.²³

That is why the marketing line "under the tongue absorbs better" is too simple for B12. A sublingual format can bypass some upstream gastrointestinal steps. The comparative studies, however, do not show a clear clinical win over high-dose oral B12 replacement when both deliver free crystalline vitamin B12 at adequate doses.⁴⁵⁶

Why intrinsic factor is the real bottleneck in vitamin B12 absorption

Vitamin B12 absorption is unusually dependent on physiology. B12 in food is protein-bound, so gastric acid and pepsin have to release it first. It then binds haptocorrin in the stomach, transfers to intrinsic factor in the small intestine, and finally reaches the cubam receptor in the terminal ileum, where the body performs the high-efficiency uptake step.¹² Intrinsic factor is the glycoprotein made by gastric parietal cells that escorts B12 to that receptor. Without it, the efficient pathway largely fails.

Green and colleagues describe B12 deficiency as a disorder that often begins with a breakdown in one of those transport steps rather than a simple lack of intake.¹ Older age, autoimmune pernicious anemia, gastric surgery, pancreatic insufficiency, ileal disease, and prolonged acid suppression all increase the chance that a normal swallowed route will underperform.¹³ That is the real reason people become interested in alternative delivery formats.

Carmel makes the clinical point plainly: once intrinsic-factor-mediated absorption is damaged, physiologic oral uptake is no longer dependable, so replacement shifts from elegance to arithmetic.³ You either bypass the gut with injection, or you push enough free crystalline B12 through the gut that passive diffusion delivers a clinically useful amount.

For a formulator, that changes the design brief. The question stops being "How large a number can I print on the front label?" and becomes "Can I deliver the same free dose every time, in a format the user will actually take consistently?" That is a much better question for B12 than the usual dose race.

What high-dose oral B12 does after the efficient pathway saturates

The most useful number in this topic is not a serum level. It is the saturation point of the intrinsic-factor system.

The NIH Office of Dietary Supplements summarizes the evidence this way: intrinsic factor can mediate absorption of about 50% of a dose when intake is under 1 to 2 mcg, but efficiency falls sharply as the dose rises. At roughly 25 mcg, only about 5% is absorbed. At 500 mcg, only about 2% is absorbed. At 1,000 mcg, only about 1.3% is absorbed.² Those percentages sound poor until you remember the arithmetic. One point three percent of 1,000 mcg still yields about 13 mcg absorbed, which is several times the adult daily requirement.

That is the real logic behind high-dose oral B12 therapy. It is redundant by design. If the normal receptor-mediated pathway is unreliable, the product can still work because a small passive fraction survives the trip.²³

Doets and colleagues' systematic review helps frame why this matters in everyday dosing, not only in deficiency rescue. They estimated daily B12 losses at about 0.13% of body stores and derived average bioavailability assumptions that are far lower than casual supplement marketing suggests.⁷ In other words, the body is careful with B12, and replacement strategy has to respect that physiology.

What the comparative studies show about sublingual vs oral B12

This is where the topic usually gets oversold.

The evidence does support alternative replacement routes for deficiency. A Cochrane review of randomized trials concluded that oral B12 doses of 1,000 to 2,000 mcg per day may be as effective as intramuscular B12 for normalizing serum levels, although the evidence base was small and low quality.⁶ Gomollon and colleagues reported that oral cyanocobalamin replacement was effective in patients with Crohn's disease as well, which is useful because Crohn's is a classic setting for ileal-related B12 trouble.⁸

The sharper question, though, is whether sublingual B12 outperforms oral B12 when the dose is already high. The answer from the direct comparative studies is no clear advantage. Sharabi and colleagues compared sublingual and oral replacement in vitamin B12 deficiency and found similar responses between the two routes.⁴ Yazaki and colleagues reached a similar conclusion in a randomized pilot study of methylcobalamin: oral and sublingual supplementation produced comparable serum responses rather than a decisive sublingual advantage.⁵

That pattern makes pharmacologic sense. A sublingual tablet, lozenge, or strip does not guarantee that the entire dose crosses the oral mucosa. Much of it is still swallowed with saliva. Once that happens, the product is back in the same high-dose passive-diffusion math as an ordinary tablet.²³ The route changes the front end of the experience, but not necessarily the clinical outcome.

The takeaway from the table is not that route never matters. It matters most when it changes the biology that would otherwise fail. For B12, that means bypassing food release and compensating for a saturated or broken intrinsic-factor pathway. It does not mean every under-the-tongue format automatically beats every swallowed tablet.

What this means for MIHIYO products

For MIHIYO, the useful design lesson is restraint.

If I am thinking about a B12 strip for Energy + Focus, I do not see a reason to build the product around the biggest milligram number that will fit on a badge. I see a reason to build it around a controlled free dose, clean mouthfeel, fast wetting, and unit-dose consistency. The intrinsic-factor system is already narrow. After that, the replacement strategy is mostly about dependable delivery, not theatrical overloading.

That is where an oral dissolving strip still has a coherent role. A strip can remove the need for water, start oral contact immediately, and make it easier to carry a precise dose than a bulk bottle of tablets. What the evidence does not let me claim is that a strip automatically creates a larger clinical B12 response than a well-made high-dose oral tablet.⁴⁵

So the honest product argument is narrower and stronger. Use the strip because the format is cleaner, more precise, and better aligned with the way people actually use portable supplements. Do not use the strip as a shortcut around the fact that most comparative B12 studies show parity, not route magic. Readers who want the bigger dosage-form framework can pair this article with our earlier pieces on why dosage form matters and oral dissolving strips versus tablets.

The studies cited here were run on vitamin B12 and replacement routes in research or clinical settings. They were not run on MIHIYO products.

Where this approach falls short

There are clear limits to the sublingual-B12 story.

First, deficiency treatment is not only a dosage-form decision. If a person has neurologic symptoms, severe anemia, unexplained weight loss, or suspected pernicious anemia, the real issue is diagnosis and medical follow-up, not choosing between a lozenge and a tablet.¹³ The format is downstream of that problem.

Second, sublingual use is behavior-dependent. If the product is swallowed immediately, most of the dose behaves like an ordinary oral supplement. That does not make it ineffective, but it does weaken the case for talking about mucosal absorption as if it were guaranteed.

Third, B12 deficiency is heterogeneous. Food-cobalamin malabsorption, ileal resection, Crohn's disease, autoimmune pernicious anemia, and low intake do not behave the same way.¹⁸ The route that looks elegant in one setting can be secondary in another.

Finally, very high-dose oral replacement works in part because the doses are so high. That can be practical, but it is also an admission that the efficient physiologic pathway is no longer doing the job. I think it is better to call it what it is: a workaround.

The bottom line

Sublingual B12 absorption matters because vitamin B12 has one of the most failure-prone uptake pathways in nutrition: food release, intrinsic factor, and ileal transport all have to line up. A sublingual or oral dissolving strip can bypass some of those early steps and make free crystalline B12 easier to use, but the comparative studies do not show a clear superiority over high-dose oral B12. The most important number is still the saturation math: once the efficient pathway tops out at about 1 to 2 mcg, replacement becomes a dose-delivery problem. That is why the strongest MIHIYO point of view here is precision and usability, not hype about route alone.

References

1. Green R, Allen LH, Bjorke-Monsen AL, Brito A, Gueant JL, Miller JW, Molloy AM, Nexo E, Stabler S, Toh BH, Ueland PM, Yajnik C. Vitamin B12 deficiency. Nat Rev Dis Primers. 2017;3:17040. PMID: 28660890. DOI: 10.1038/nrdp.2017.40. <https://pubmed.ncbi.nlm.nih.gov/28660890/>
2. National Institutes of Health Office of Dietary Supplements. Vitamin B12 - Health Professional Fact Sheet. Updated April 9, 2025. <https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/>
3. Carmel R. How I treat cobalamin (vitamin B12) deficiency. Blood. 2008;112(6):2214-2221. PMID: 18606874. PMCID: PMC2532799. <https://pubmed.ncbi.nlm.nih.gov/18606874/>
4. Sharabi A, Cohen E, Sulkes J, Garty M, Loewenthal N. Replacement therapy for vitamin B12 deficiency: comparison between the sublingual and oral route. Br J Clin Pharmacol. 2003;56(6):635-638. PMID: 14616423. <https://pubmed.ncbi.nlm.nih.gov/14616423/>
5. Yazaki Y, Chow G, Mattie M. A single-center, double-blinded, randomized controlled study to evaluate the relative efficacy of oral and sublingual vitamin B-complex administration in reducing total serum homocysteine levels. J Altern Complement Med. 2006;12(9):881-885. PMID: 17109579. <https://pubmed.ncbi.nlm.nih.gov/17109579/>
6. Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev. 2018;3(3):CD004655. PMID: 29543316. <https://pubmed.ncbi.nlm.nih.gov/29543316/>
7. Doets EL, In 't Veld PH, Szczecinska A, Dhonukshe-Rutten RA, Cavelaars AE, van 't Veer P, Brzozowska A, de Groot LC. Systematic review on daily vitamin B12 losses and bioavailability for deriving recommendations on vitamin B12 intake with the factorial approach. Ann Nutr Metab. 2013;62(4):311-322. PMID: 23796635. DOI: 10.1159/000346968. <https://pubmed.ncbi.nlm.nih.gov/23796635/>
8. Gomollon F, Gargallo-Puyuelo CJ, Munoz JF, Vicente R, Sebastian B, Martin-Arranz MD, Garcia-Erce JA. Oral cyanocobalamin is effective in the treatment of vitamin B12 deficiency in Crohn's disease. Nutrients. 2017;9(4):308. PMID: 28335526. <https://pubmed.ncbi.nlm.nih.gov/28335526/>

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.